Alembic Pharmaceuticals Limited (APLLTD) — Announcement
Alembic Pharmaceuticals announced that the USFDA granted final approval for its Tretinoin Cream USP, 0.05% ANDA, a therapeutically equivalent generic to Retin-A Cream indicated for acne vulgaris. The product targets an estimated US$ 76 million market and marks the company's 242nd USFDA approval, including 222 final approvals. This regulatory milestone strengthens Alembic's US generic portfolio and expands its presence in a key therapeutic area.
About Alembic Pharmaceuticals Limited (APLLTD)
Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE
📡 Get AI alerts when APLLTD files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track APLLTD — Free💡 Ask AI about this filing
📊 More APLLTD filings
- 🔴 Annual Report — 10 July 2026 Alembic Pharmaceuticals announced its 16th Annual General Meeting on 5 August 2026 via video confere...
- 🔴 Corporate Action — 10 July 2026 Alembic Pharmaceuticals announced a record date of 29 July 2026 for dividend entitlement on FY2026 s...
- 🔴 Announcement — 1 July 2026 Alembic Pharmaceuticals reaffirmed its CRISIL AA+/Stable rating on a revalued Rs. 1,100 crore bank l...
- Announcement — 26 June 2026 Alembic Pharmaceuticals announced USFDA final approval for Oseltamivir Phosphate Oral Suspension 6 m...
- Financial Results — 26 June 2026 Alembic Pharmaceuticals announced that its trading window will close on 1 July 2026 and remain close...
🔥 Also filed on 12 June 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
📡 Get AI alerts when APLLTD files new disclosures
Track APLLTD filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track APLLTD — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research